News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
570,048 Results
Type
Article (50628)
Company Profile (127)
Press Release (519293)
Section
Business (155993)
Career Advice (2454)
Deals (29098)
Drug Delivery (121)
Drug Development (71516)
Employer Resources (154)
FDA (15851)
Job Trends (12584)
News (279976)
Policy (30598)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2659)
Academic (1)
Accelerated approval (5)
Adcomms (29)
Allergies (80)
Alliances (39995)
ALS (84)
Alzheimer's disease (1479)
Antibody-drug conjugate (ADC) (127)
Approvals (15812)
Artificial intelligence (241)
Autoimmune disease (21)
Automation (11)
Bankruptcy (317)
Best Places to Work (9738)
BIOSECURE Act (21)
Biosimilars (110)
Biotechnology (77)
Bladder cancer (62)
Brain cancer (26)
Breast cancer (251)
Cancer (1984)
Cardiovascular disease (176)
Career advice (2053)
Career pathing (32)
CAR-T (148)
Cell therapy (406)
Cervical cancer (20)
Clinical research (57803)
Collaboration (719)
Compensation (467)
Complete response letters (29)
COVID-19 (2650)
CRISPR (42)
C-suite (208)
Cystic fibrosis (95)
Data (1871)
Decentralized trials (2)
Denatured (14)
Depression (48)
Diabetes (252)
Diagnostics (5636)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (99)
Drug pricing (118)
Drug shortages (32)
Duchenne muscular dystrophy (90)
Earnings (60269)
Editorial (40)
Employer branding (20)
Employer resources (139)
Events (82675)
Executive appointments (603)
FDA (16974)
Featured Employer (35)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (649)
Gene editing (102)
Generative AI (21)
Gene therapy (303)
GLP-1 (769)
Government (4028)
Grass and pollen (5)
Guidances (46)
Healthcare (16088)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (126)
Indications (23)
Infectious disease (2787)
Inflammatory bowel disease (132)
Inflation Reduction Act (9)
Influenza (46)
Intellectual property (83)
Interviews (451)
IPO (14379)
IRA (48)
Job creations (3252)
Job search strategy (1712)
Kidney cancer (10)
Labor market (28)
Layoffs (502)
Leadership (20)
Legal (7199)
Liver cancer (71)
Lung cancer (286)
Lymphoma (134)
Machine learning (4)
Management (53)
Manufacturing (265)
MASH (65)
Medical device (11628)
Medtech (11631)
Mergers & acquisitions (15184)
Metabolic disorders (684)
Multiple sclerosis (73)
NASH (22)
Neurodegenerative disease (94)
Neuropsychiatric disorders (31)
Neuroscience (1987)
NextGen: Class of 2025 (5364)
Non-profit (3748)
Northern California (2316)
Now hiring (19)
Obesity (381)
Opinion (229)
Ovarian cancer (72)
Pain (83)
Pancreatic cancer (74)
Parkinson's disease (141)
Partnered (15)
Patents (206)
Patient recruitment (92)
Peanut (46)
People (46768)
Pharmaceutical (38)
Pharmacy benefit managers (21)
Phase I (17528)
Phase II (25113)
Phase III (20133)
Pipeline (1065)
Podcasts (78)
Policy (137)
Postmarket research (2333)
Preclinical (7243)
Press Release (38)
Prostate cancer (94)
Psychedelics (35)
Radiopharmaceuticals (224)
Rare diseases (383)
Real estate (4679)
Recruiting (61)
Regulatory (21436)
Reports (32)
Research institute (2469)
Resumes & cover letters (408)
Rett syndrome (4)
RNA editing (3)
RSV (45)
Schizophrenia (73)
Series A (118)
Series B (74)
Service/supplier (9)
Sickle cell disease (56)
Southern California (1971)
Special edition (16)
Spinal muscular atrophy (135)
Sponsored (32)
Startups (3039)
State (1)
Stomach cancer (16)
Supply chain (66)
Tariffs (14)
The Weekly (63)
United States (19681)
Vaccines (742)
Venture capitalists (39)
Webinars (12)
Weight loss (281)
Women's health (31)
Worklife (19)
Date
Last 7 days (629)
Last 30 days (2365)
Last 365 days (31187)
2025 (7987)
2024 (32641)
2023 (36457)
2022 (46794)
2021 (50506)
2020 (47766)
2019 (38964)
2018 (29490)
2017 (29384)
2016 (27842)
2015 (30549)
2014 (24106)
2013 (19975)
2012 (21312)
2011 (21661)
2010 (19655)
Location
Africa (730)
Alabama (42)
Alaska (6)
Arizona (174)
Arkansas (11)
Asia (33795)
Australia (6079)
California (5189)
Canada (1498)
China (396)
Colorado (225)
Connecticut (255)
Delaware (128)
Europe (81043)
Florida (791)
Georgia (177)
Hawaii (1)
Idaho (40)
Illinois (440)
India (23)
Indiana (261)
Iowa (9)
Japan (137)
Kansas (86)
Kentucky (16)
Louisiana (7)
Maine (62)
Maryland (811)
Massachusetts (3921)
Michigan (172)
Minnesota (318)
Mississippi (1)
Missouri (68)
Montana (16)
Nebraska (20)
Nevada (50)
New Hampshire (56)
New Jersey (1486)
New Mexico (19)
New York (1473)
North Carolina (882)
North Dakota (7)
Northern California (2316)
Ohio (165)
Oklahoma (10)
Oregon (30)
Pennsylvania (1146)
Puerto Rico (9)
Rhode Island (18)
South America (1104)
South Carolina (17)
South Dakota (1)
Southern California (1971)
Tennessee (84)
Texas (755)
Utah (146)
Virginia (119)
Washington D.C. (60)
Washington State (480)
West Virginia (3)
Wisconsin (49)
570,048 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
·
1 min read
·
Annalee Armstrong
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Alzheimer’s disease
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Cycle Pharma Acquires Banner Life Sciences, LLC
January 13, 2025
·
17 min read
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
March 28, 2025
·
4 min read
1 of 57,005
Next
